Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Monte Rosa Therapeutics, Inc. has filed an automatic shelf registration and a related at-the-market program to sell up to $100,000,000 of common stock through Jefferies on a commission of 3% of gross proceeds. Shares will be sold from time to time at market prices.
The company plans to use any net proceeds for general corporate purposes, including research and clinical development of its molecular glue degrader pipeline, working capital, capital expenditures and office expansion. Monte Rosa remains an emerging growth and smaller reporting company with lead programs in immunology, inflammation and oncology.
Monte Rosa Therapeutics, Inc. reported that Edmund Dunn plans to retire from his role as Senior Vice President, Corporate Controller and Principal Accounting Officer, effective April 3, 2026. The company states that his retirement is not due to any disagreement over operations, policies, or practices and that he will not receive severance payments or benefits tied to his departure.
Effective the same date, Matthew Bowen, age 37, will become Corporate Controller and Principal Accounting Officer. Bowen joined Monte Rosa’s finance department after its June 2021 initial public offering and has held roles of increasing responsibility, most recently as Director, Finance. He previously spent seven years in Ernst & Young LLP’s audit and assurance practice, primarily auditing large public companies. The filing notes there are no special arrangements, family relationships, or related-party transactions connected to his promotion.
Monte Rosa Therapeutics, Inc. has a large shareholder group reporting passive ownership of its common stock. Dimension Capital I, L.P. directly holds 5,663,265 shares of common stock, and together with affiliated entities and individuals Adam Goulburn, Zavain Dar, and Nan Li, this position represents 8.7% of the company’s outstanding shares.
The ownership percentage is calculated using 65,117,761 shares of common stock outstanding as of October 31, 2025, as disclosed in Monte Rosa’s Form 10-Q. The reporting group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Monte Rosa, indicating a passive investment stance rather than an activist position.
Monte Rosa Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 11,125,000 shares of common stock at $24.00 per share and pre-funded warrants to purchase 1,375,000 shares at $23.9999 per warrant, with each warrant having a $0.0001 exercise price. The company also granted underwriters a 30-day option to buy up to 1,875,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
Monte Rosa estimates net proceeds of approximately $281.6 million from this offering, excluding any proceeds from the underwriters’ option. It plans to use the cash, together with existing balances, to advance MRT-8102 in chronic inflammatory diseases including atherosclerotic cardiovascular disease, further develop its QuEENTM platform across immunology, inflammation and oncology targets, and for working capital and general corporate purposes. The offering is expected to close on or about January 12, 2026, and the company expects its cash and cash equivalents to fund planned operations and capital expenditures into 2029.
Monte Rosa Therapeutics, Inc. is offering 11,125,000 shares of common stock and pre-funded warrants to purchase 1,375,000 shares at $24.00 per share (or $23.9999 per pre-funded warrant). The deal is underwritten, includes a 30‑day option for underwriters to buy up to 1,875,000 additional shares, and is expected to deliver approximately $281.6 million in net proceeds, or about $323.9 million if the option is fully exercised. After this financing, the company expects its cash, cash equivalents and marketable securities to fund operations into 2029.
Management plans to use the cash to advance lead candidate MRT-8102 in chronic inflammatory diseases including ASCVD, and to further develop and deploy its QuEENTM molecular glue degrader discovery platform across immunology, inflammation and oncology targets, as well as for general corporate purposes. The pre-funded warrants have a de minimis $0.0001 exercise price, no expiry, ownership caps between 4.99% and 19.99%, and will not be listed, while investors in this offering will experience immediate and substantial dilution versus net tangible book value.
Versant-affiliated funds reported a lower ownership stake in Monte Rosa Therapeutics, Inc. In Amendment No. 6 to their Schedule 13D, the reporting persons disclose aggregate beneficial ownership of 3,250,069 shares of Common Stock, representing 4.99% of the company’s outstanding shares, based on 65,117,761 shares outstanding as of October 31, 2025. The holdings consist of 2,236,708 shares held by Versant Venture Capital VI, L.P. and 1,013,361 shares held by Versant Vantage I, L.P.
The filing details recent activity, including several open-market sales and pro rata distributions to limited partners. Versant VI sold 15,200 shares at a weighted average price of $14.2503 on November 19, 2025, 10,205 shares at $17.64 on December 16, 2025, and 572,526 shares at a weighted average price of $23.3304 on January 7, 2026. Versant VI also distributed 500,030 shares to its limited partners on December 4, 2025, and Versant Vantage I distributed 560,092 shares on January 8, 2026, both on a pro rata basis without additional consideration.
Monte Rosa Therapeutics, Inc. President & CEO Markus Warmuth reported open-market sales of company common stock on January 7, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025. He sold 3,707 shares at a weighted average price of $23.2422, 1,450 shares at $23.8762, and 309 shares at $24.5736, for a total of 5,466 shares sold.
The filing notes that each weighted average price reflects multiple trades, with sale prices ranging from $22.42 to $24.65. After these transactions, Warmuth beneficially owned 618,937 shares of Monte Rosa common stock in direct ownership.
Monte Rosa Therapeutics filed an amended Form 144 notice covering a planned stock sale. The filing indicates a proposed sale of 5,466 shares of common stock through broker Rockefeller Capital Management on the NASDAQ, with an approximate sale date of January 7, 2026.
The securities to be sold stem from a restricted stock unit (RSU) stock award for 21,865 units, acquired on January 2, 2025 from the issuer as compensation, with the payment date listed as January 2, 2026.
The document also reports that seller Markus Warmuth sold 10,135 Monte Rosa Therapeutics shares on January 5, 2026, generating gross proceeds of $153,759.
GLUE filed a Rule 144 notice for a planned stock sale. The filing covers a proposed sale of 5,466 shares of common stock through Rockefeller Capital Management, with an aggregate market value of $128,372.00. The shares are expected to be sold on or about January 7, 2026 on the NASDAQ, and the issuer had 65,117,761 shares outstanding.
The securities to be sold are tied to a stock award of 21,865 RSUs acquired on January 2, 2025 from the issuer as compensation, with a stated payment date of January 2, 2026. The person on whose behalf the sale is planned represents that they do not know of any material adverse, nonpublic information about the issuer’s current or prospective operations, and the form allows for reliance on a Rule 10b5-1 trading plan if such a plan date is indicated.
Monte Rosa Therapeutics, Inc. reported that, effective January 7, 2026, it terminated the sales agreement prospectus used for its at-the-market (“ATM”) equity program under its Form S-3 registration statement. This means the company will not sell additional shares of its common stock under the existing Open Market Sale Agreement with Jefferies LLC unless and until it files a new prospectus, prospectus supplement, or a new registration statement.
The underlying Sales Agreement with Jefferies LLC, originally dated July 1, 2022 and amended March 20, 2025, remains in full force and effect apart from the ATM prospectus termination. As of January 7, 2026, the company had issued and sold 2,955,082 shares of common stock under this arrangement, generating aggregate net proceeds of $24.2 million.